A5076343086- Virus-based gene therapy research
- Cancer Research and Treatments
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Immune cells in cancer
- Parasitic Infections and Diagnostics
- Retinal Diseases and Treatments
- Psoriasis: Treatment and Pathogenesis
- Angiogenesis and VEGF in Cancer
- Retinal Development and Disorders
- Plant and Fungal Interactions Research
- Cancer, Hypoxia, and Metabolism
- Glaucoma and retinal disorders
- Peptidase Inhibition and Analysis
- Viral gastroenteritis research and epidemiology
- Mesenchymal stem cell research
- Chemokine receptors and signaling
- Phagocytosis and Immune Regulation
- Monoclonal and Polyclonal Antibodies Research
- Pluripotent Stem Cells Research
- interferon and immune responses
- Pancreatic function and diabetes
State Key Laboratory of Biotherapy
2012-2023
Sichuan University
2012-2023
Zhejiang University
2008-2009
Zhejiang University of Science and Technology
2008
Genesys (United States)
2002-2006
Johns Hopkins University
2001-2004
University of California, San Francisco
1995-2004
CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue. In previous phase I/II clinical trial of intraprostatic delivery for locally recurrent cancer this virus was well tolerated. I study administered as single intravenous infusion group-sequential dose escalation design (1 × 1010 6 1012 viral particles (vp)) 23 patients with hormone-refractory metastatic cancer. Flulike symptoms (fever, fatigue, rigors, nausea, and/or...
Abstract Purpose: The purpose of this study was to examine the tumor specificity, cytotoxicity, and granulocyte macrophage colony-stimulating factor expression CG0070, a conditionally replicating oncolytic adenovirus, in human bladder transitional cell carcinoma (TCC) lines determine its antitumor efficacy TCC models. Experimental Design: Virus yield cytotoxicity assays were used specificity virus replication-mediated CG0070 panel primary cells vitro. Two s.c. one orthotopic xenograft models...
Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety malignancies. Sintilimab, highly selective, fully human monoclonal antibody (mAb), blocks the interaction PD-1 and its ligands benefit in various studies. Here, we evaluated affinity sintilimab to surface plasmon resonance mesoscale discovery receptor occupancy anti-tumor humanized NOD/Shi-scid-IL2rgamma (null) (NOG) mouse model. We also...
Autologous adipose tissue or with additive adipose-derived mesenchymal stem cells (ADSCs) is used in the breast reconstruction of cancer patients who undergo mastectomy. ADSCs play an important role angiogenesis and adipogenesis, which make it much better than other materials. However, may promote residual tumor to proliferate metastasize, mechanism still not fully understood. In this study, we demonstrated that human (hADSCs) could facilitate growth after co-injection MCF7 ZR-75-30 (BCCs)...
Immunotherapy based on the immune checkpoint blockade has emerged as most promising approach for cancer therapy. However, proportion of colorectal patients who benefit from immunotherapy is small due to immunosuppressive tumor microenvironment. Hence, combination an ideal strategy overcome this limitation. In study, we developed a novel CSF-1R (colony-stimulating factor 1 receptor) inhibitor (PLX3397), oncolytic viruses, and anti-PD-1 antibody. Our results demonstrated that triple treatment...
SARI, also called as BATF2, belongs to the BATF family and has been implicated in cancer cell growth inhibition. However, role mechanism of SARI tumour angiogenesis are elusive. Here we demonstrate that deficiency facilitates AOM/DSS-induced colonic tumorigenesis mice. We show is a novel inhibitor colon Antibody array HUVEC-related assays indicate VEGF an essential SARI-controlled inhibition angiogenesis. Furthermore, Co-IP/PAGE/mass spectrometry indicates directly targets ceruloplasmin...
IL-35 downregulates Th17 cell development and suppresses certain types of autoimmune inflammation such as collagen-induced arthritis experimental uveitis. Psoriasis is thought to be initiated by abnormal interactions between cutaneous keratinocytes systemic immune cells. However, the role in psoriasis remains unclear. In this study, we assessed three well-known models: a human keratinocyte line (HaCaT), keratin 14 (K14)-vascular endothelial growth factor A (VEGF-A)-transgenic (Tg) mouse...
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority do not respond to it. Resistance cancer immunotherapy can be mediated by additional immune checkpoints. We hypothesized that co-targeting PD-L1 and lymphocyte-activation gene 3 (LAG-3) could provide an alternative therapeutic approach. Here, we developed IBI323, dual blockade bispecific antibody targeting LAG-3.We assessed binding...
Antiangiogenesis therapies targeting vascular endothelial growth factor (VEGF) have revolutionized the treatment of neovascular ocular diseases, including age-related macular degeneration (nAMD). Compelling evidence has implicated vital role complement system dysregulation in AMD pathogenesis, implying it as a potential therapeutic strategy for geographic atrophy dry and to enhance efficacy anti-VEGF monotherapies nAMD. This study reports preclinical assessment phase 1 clinical outcomes...
Pre-existent humoral antibody to adenovirus potentially confounds human clinical trials involving intravascular administration of adenovirus. Using the LNCaP prostate cancer xenograft model in BALB/c nu/nu mice and prostate-specific attenuated replication-competent (ARCA™) CN706, we developed an animal that systematically controls both dose intravascularly administered titer pre-existent anti-Ad5 antibody, then measures virus-induced toxicity as well antitumor activity. We prepared...
Abstract Interleukin‐35 ( IL ‐35), a member of the ‐12 family, functions as new anti‐inflammatory factor involved in arthritis, psoriasis, inflammatory bowel disease IBD ) and other immune diseases. Although ‐35 can significantly prevent development inflammation many diseases, there have been no early studies accounting for role recombinant protein psoriasis. In this study, we assessed therapeutic potential three well‐known mouse models: dextransulfate sodium DSS )‐induced colitis model,...
Paclitaxel (PTX) has shown pleiotropic immunologic effects on the tumor microenvironment, and nanomicelle emerged as a promising strategy for PTX delivery. However, detailed mechanisms remain to be fully elucidated. Meanwhile, immunogenic cell death (ICD) is an effective approach activate immune system. This study investigated ICD effect of how affected immune-activation ability PTX. Methods: The were identified via expression markers vaccine experiment. Tumor size overall survival in...
Ad5, adenovirus type 5; CNE, human nasopharyngeal carcinoma cell line; DLT, dose- limiting toxicity; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNC, head and neck cancer; HRP,horseradish peroxidase; hTERT, telomerase reverse transcriptase; IL, interleukin; mtelo, modified promoter; MTD, maximum- tolerated dose; NCI-CTC, National Cancer Institute Common Toxicity Criteria; PCR, polymerase chain reaction; SDS-PAGE,sodium dodecyl sulphate polyacrylamide gel electrophoresis; SCHNC,...
Abstract Dexamethasone (Dex), as a pretreatment agent, is widely used to attenuate the side effects of chemotherapy in breast cancer treatment. However, whether and how Dex affects metastasis remain be furtherly understood. In this study, we established several mouse metastatic models study effect vitro vivo. Transwell, Western Blot RNA interference were applied molecular mechanism promoting cell migration. Meanwhile, on lung combined with PTX was discussed. Our results confirmed that could...
Abstract Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T-cell activation. A promising strategy for cancer immunotherapy is to disrupt key pathways regulating immune tolerance, such as program death-1 (PD-1/PD-L1) pathway in the tumor environment. However, determinants of response anti-PD-1 monoclonal antibodies (mAbs) treatment remain incompletely understood. In murine models, PD-1 blockade alone fails induce effective...